MK-677: The Oral Growth Hormone Secretagogue With 15 RCTs

MK-677 (ibutamoren) is technically not a peptide — it's a non-peptide ghrelin receptor agonist that mimics the growth hormone secretagogue peptide ghrelin. But it's included in the Peptide List because it acts on the same axis and is widely discussed alongside injectable GH-releasing peptides. Its unique advantage is oral bioavailability. While most GH secretagogues require injection, MK-677 can be taken by mouth — which has made it one of the most accessible and widely studied compounds in this class.

MK-677 has approximately 15 published RCTs — a rare evidence base for a compound that's not FDA-approved. Key findings across trials: • Robust GH and IGF-1 elevation: Consistently increases 24-hour GH secretion and raises IGF-1 levels by 40-60% across multiple trials, including in elderly and GH-deficient populations. • Body composition: The pivotal 2-month obesity trial showed increased fat-free mass and energy expenditure. A 12-month trial in elderly subjects showed increased GH secretion to youthful levels without serious adverse events. • Bone density: Multiple trials showed increases in bone turnover markers. Combined with alendronate, MK-677 produced additive effects on bone mineral density in postmenopausal women. • Sleep quality: One of the most replicated findings — MK-677 increases Stage IV (deep) sleep duration by approximately 50% and REM sleep by 20%.

MK-677's side effects reflect its mechanism — chronic ghrelin receptor activation has consequences: • Increased appetite and potential weight gain (ghrelin is the "hunger hormone") • Mild insulin resistance and elevated fasting glucose in some trials • Water retention and edema, particularly in the first weeks • Theoretical concern about prolonged IGF-1 elevation and cancer risk (unproven but biologically plausible) The 2-year trial in elderly subjects did not show increased cancer incidence, but the study wasn't powered to detect this. The insulin sensitivity concern is real and should be monitored in anyone using MK-677 long-term.

Despite substantial clinical data, MK-677 was never brought to FDA approval. Merck (the developer) shelved it after the compound failed to meet primary endpoints in larger trials for specific indications like hip fracture prevention and sarcopenia. The drug "worked" in terms of raising GH and IGF-1, but translating that into hard clinical endpoints proved difficult. This is an important lesson for the GH-axis peptide space broadly: raising growth hormone levels is easy to measure but hard to translate into the outcomes that matter — fracture prevention, functional independence, mortality reduction.